The efficacy of immune checkpoint therapy in mismatch repair proficient (pMMR) and microsatellite stable (MSS) ICC is still unclear, and the predictive effect of tumour mutation burden (TMB) and PD-L1 expression status is also inconclusive [45–47]. The gene discussed is CD274; the disease is neoplasm.